Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #65 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Aarti Drugs Limited (this stock) | 3,788 | 22.1 | 12.6% | -16.9% | 0.48% | 67 | 59 | 51 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 703 | 69 | 50 | ₹ |
| March 31, 2026 | 720 | 70 | 55 | ₹ |
| Dec. 31, 2025 | 602 | 29 | 41 | ₹ |
| Sept. 30, 2025 | 653 | 60 | 45 | ₹ |
| June 30, 2025 | 591 | 51 | 54 | ₹ |
| March 31, 2025 | 677 | 71 | 63 | ₹ |
| Dec. 31, 2024 | 557 | 51 | 37 | ₹ |
| Sept. 30, 2024 | 598 | 46 | 35 | ₹ |
| June 30, 2024 | 555 | 44 | 33 | ₹ |
| March 31, 2024 | 620 | 64 | 47 | ₹ |
| Dec. 31, 2023 | 606 | 52 | 37 | ₹ |
| Sept. 30, 2023 | 642 | 56 | 40 | ₹ |
| June 30, 2023 | 661 | 64 | 48 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 2,565 | 211 | 195 |
| March 31, 2025 | 2,387 | 212 | 168 |
| March 31, 2024 | 2,529 | 236 | 172 |
| March 31, 2023 | 2,716 | 224 | 166 |
| March 31, 2022 | 2,489 | 270 | 205 |
| March 31, 2021 | 2,155 | 369 | 280 |
| March 31, 2020 | 1,806 | 185 | 141 |
| March 31, 2019 | 1,561 | 131 | 90 |
| March 31, 2018 | 1,263 | 125 | 82 |
| March 31, 2017 | 1,263 | 125 | 82 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 254 | -173 | -77 | 173 | 80 |
| March 31, 2025 | 245 | -165 | -82 | 177 | 67 |
| March 31, 2024 | 359 | -224 | -136 | 226 | 133 |
| March 31, 2023 | 134 | -164 | 17 | 165 | -30 |
| March 31, 2022 | 70 | -149 | 92 | 144 | -74 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 2,815 | 1,549 | 1,458 | 318 | 257 | 1,468 | 922 | 7 | 1,068 | 491 |
| March 31, 2025 | 2,575 | 1,369 | 1,278 | 328 | 284 | 1,338 | 837 | 5 | 856 | 473 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
